Profhilo Structura: How It Differs From Standard Profhilo

You have noticed a little less fullness near your cheekbones and been offered Profhilo Structura with the promise of “restoring your own volume without filler.” It sounds appealing, but before accepting injections, separate the product's intended design from expectations. Profhilo Structura is a specific injectable hyaluronic-acid product marketed for facial tissue, including superficial cheek fat compartments. It is not surgery, does not guarantee restoration of lost fat and is not the same as standard Profhilo, commonly discussed in relation to skin quality. The decision is whether the proposed change fits your anatomy and whether the injection risks are worthwhile for a possibly subtle effect.

How to distinguish Profhilo Structura from standard Profhilo

The product family is developed by IBSA; the device documentation names IBSA Farmaceutici Italia Srl. Instead of focusing only on skin hydration, Structura is presented as addressing age-related changes in facial subcutaneous tissue. It uses complexes of high- and low-molecular-weight hyaluronic acid made with NAHYCO technology. Manufacturer documentation lists 45 mg of high- and 45 mg of low-molecular-weight hyaluronic acid in a 2 mL syringe, 90 mg total; a 1 mL syringe contains 22.5 mg of each type, 45 mg total. Those are composition facts, not clinical outcome guarantees.

The packaging, device record and consent form should carry the same complete name—not plain Profhilo, Profhilo Body or a vague “skin revitaliser.” The extra word “advanced” in search terms and marketing does not by itself establish a separate formula or newer model. If a clinic advertises “Profhilo Structura Advanced,” ask what exactly the original instructions and packaging say, including batch number and expiry date. Injection technique, indications and studies cannot be borrowed indiscriminately from other hyaluronic-acid products.

What does marketing promise, and what have studies actually shown?

The proposed target is age-related soft-tissue change in the lateral or outer cheek. An observational pilot published in 2024 enrolled 50 people who received two treatments one month apart and were assessed afterward. Researchers reported changes in facial volume-loss and wrinkle-severity scores during follow-up. A 2023 case series described 22 participants followed for up to six months. Both provide preliminary information, not proof that youthful fat returns in every patient.

Why does this distinction matter? As of October 2026, published clinical evidence specifically for Structura still comes mainly from small uncontrolled studies; without large, independent randomised studies with appropriate comparisons, we cannot reliably separate biological “fat regeneration” from the presence and distribution of injected gel, temporary volume change, tissue responses or measurement effects. Some authors of the publications were affiliated with the manufacturer, requiring careful interpretation. Cell and animal experiments do not show that the product reliably rebuilds human subcutaneous fat over the long term. “Regeneration” in marketing is not an individual clinical promise.

Which concerns might it address, and what can it not do?

A good clinician should explain possible changes from the front and in profile, not merely show an attractive before-and-after image. If you mainly want a defined jawline, correction of deep nasolabial folds or substantial lifting, compare other options. Structura is not a replacement for surgical lifting, for structural fillers when there is a major support deficit, or for simple care when the problem is superficial dryness.

Will my face still look natural?

This is most useful to discuss with modest expectations. A subtle softening of shadows may be possible, but the exact result cannot be promised. Where tissue already has enough volume, adding a product could create unwanted fullness rather than a fresh appearance. Assessment depends on fat distribution, bone support, skin thickness, previous injections and technique. Look at the face in motion, smiling and in everyday light, not just one flattering profile photo.

Do not confuse “does not look like filler” with “does not add volume.” Anything injected occupies physical space at first and later changes within the tissue. An entirely invisible intervention for everyone is not a realistic promise. You may request a conservative plan, review it after initial reactions have fully settled or decline altogether if the likely change feels too uncertain.

What happens at the visit, and why does injection depth matter?

Consultation should include medical history, assessment of skin and soft tissue and disclosure of previous injected products and health conditions. Published studies used cannulas—slender, blunt-tipped tubes—with access near the ear and placement in specific superficial fat layers. The product instructions allow both needles and cannulas; this choice should not depend on an advertisement. Research protocols are not instructions for self-treatment and are not a universal plan for every patient. Exact sites, depth and technique must follow the current instructions for that product and the clinician's competence.

A puncture, pressure, stretching sensation and moderate discomfort are possible; tolerance varies, so assume neither zero pain nor a standard level of pain. Ask whether local anaesthesia is planned and suitable for your health situation. Check that the clinician has product information, emergency resources and a plan for suspected vascular complications. Cannulas may reduce some mechanical risks compared with needles in some circumstances, but do not eliminate facial injection risks.

When should results be judged, and when should photos be scheduled?

Immediately afterward, there may be mild swelling, puncture marks, asymmetry caused by local swelling or bruising. These are not the final result. After a few days, others may notice little, but no exact deadline can be promised; bruises sometimes remain visible longer, especially with a tendency to bruise or medicines affecting clotting. If a wedding, flight, interview or photo shoot is close, plan ahead and leave a margin instead of assuming everything will disappear by morning.

Research protocols sometimes include two sessions approximately one month apart, but an examination is needed before treating that as your personal course. Studies observed participants for months; this does not establish that the result lasts exactly six months for everyone or that injections must recur by calendar. Maintenance, if any, should follow assessment rather than automatic renewal. Arrange comparable follow-up photos and ask how transient swelling will be distinguished from the intended change.

Aftercare and the social side of recovery

The clinician should provide written aftercare specific to the administered product. In the first days, avoid massaging or pressing injection areas unless instructed, keep them clean and minimise activities that worsen swelling or irritation. The product instructions recommend avoiding ultraviolet exposure of the treated site for the next 3–5 days and using high sun protection. Ask individually when you may resume exercise, sauna, active skin products or device-based treatments. Do not conceal concerning symptoms or take medicines to “dissolve” the product on your own; this may complicate evaluation. Makeup and touching the face should depend on skin condition and medical advice, not an influencer's timetable.

Medical recovery and being comfortable socially are different things. You may feel well while a cannula entry point or a bruise remains visible through foundation. For anyone who prefers not to explain a cosmetic procedure at work, this matters more than the slogan “no downtime.” Choosing a quiet week or postponing altogether is a legitimate choice, not a missed opportunity.

Contraindications and serious warning signs after injections

Avoid aesthetic injections into infected or inflamed skin. Past allergies, bleeding disorders, anticoagulants and other medicines all matter. The official Profhilo Structura instructions say not to use it during pregnancy or breastfeeding, with autoimmune disease, known allergy to ingredients or in areas of inflammation; the site must have healthy skin. They also prohibit injection into blood vessels, muscles or tendons, mixing with other products, reuse of an opened syringe and concurrent laser resurfacing or medium-to-deep chemical peeling. Always check the current instructions for the actual supplied product and country of treatment. Do not override contraindications with a reassurance that “a small dose is safe.” Do not stop prescriptions without consulting the prescribing doctor.

Possible routine reactions include tenderness, redness, swelling and bruising; nodules, inflammation or infection may also occur. Any facial injection can involve vascular injury. The FDA warns of rare but serious complications with soft-tissue fillers, including skin ischaemia and visual impairment; its general filler risk figures cannot be assigned to Structura specifically, but the anatomical risk must not be ignored. Sudden unusual pain, white/grey/blue skin, vision changes, weakness, facial droop or speech difficulties require immediate emergency medical assistance. Do not await a routine review or try to massage the area yourself.

Registration and authenticity: what is actually known

Australia’s TGA has had two records for PROFHILO STRUCTURA: ARTG 458194, dated 1 August 2024, and ARTG 473805, dated 18 December 2024. Crucially, ARTG 458194 was cancelled at the sponsor’s request, effective 24 June 2025; the separate ARTG 473805 entry was listed as active at the time of checking (Class III; manufacturer IBSA Farmaceutici Italia Srl). Cancellation of the first record does not itself establish a safety problem, but these two historical entries must not be presented as two active registrations. Even a current Australian listing proves nothing about authorisation in Armenia, the EU or the US. A published study does not establish that a particular clinic obtains authentic syringes. Structura must not be called “FDA approved” on the basis of US decisions concerning other hyaluronic-acid fillers.

Before consent, ask to see the unopened original packaging, exact name and contents, expiry date, batch-origin details, evidence of lawful supply and use in the treatment country and the completed implant card identifying the product and batch after treatment. Check who performs the injection and the medical qualifications that permit it. If a practitioner cannot distinguish standard Profhilo from Structura, does not know the instructions or offers a previously opened syringe of unclear origin, do not proceed.

What alternatives are available, and how should cost be compared?

For predominantly dry skin, a home-care strategy or treatments intended to improve surface skin quality may suit better. For genuine localised loss of support, a clinician may discuss other fillers, their possible benefits and specific risks. When tissues have descended substantially, injections have limits and a surgical opinion may be more honest than a promise to “lift everything.” Sudden unexplained facial volume loss should be medically assessed first. Age-related change alone never obliges you to have a procedure.

Compare the justified full plan, not a promotional syringe price: assessment, verified product, proposed visits, reassessment, access to complication care and the option of doing nothing after consultation. Ask who pays for emergency care and how to reach the clinician outside normal hours. Before-and-after images and enthusiastic reviews do not substitute for risk data or show every dissatisfied patient. The issue is not which product is fashionable but whether this particular soft-tissue approach serves your aim.

A short decision guide: when not to rush

• It may be worth discussing further if your clinician identifies a clear anatomical goal, shows authentic packaging, explains the limits of the evidence and offers follow-up without promising “new fat growth.”
• Change approach if the main problem is dryness, significant tissue sagging or deep support loss that this technique cannot reliably correct.
• Stop if you have a listed contraindication, the syringe's origin is unclear, emergency care is not planned or you feel pressed to decide immediately.

This is not a substitute for an examination; it is a way to distinguish a persuasive presentation from treatment that actually suits you.

Seven questions before informed consent

1. Do you see lateral cheek volume loss or mostly tissue descent, and how did you tell the difference?
2. Does the package say Structura, not another Profhilo, and may I see the instructions and batch origin?
3. What has human research established, and what remains a hypothesis about “fat restoration”?
4. Who will inject, into which tissue layers, and what is your experience in handling complications?
5. What might I look like tomorrow, next week and at review if I develop swelling or a bruise?
6. What change is realistic for my face without excess fullness, and how will we assess it?
7. What less invasive option would you suggest if I am not ready for injections?

Additional questions

Can hyaluronidase reverse a result I dislike?

Doctors use hyaluronidase in certain circumstances with hyaluronic-acid products, but the speed and completeness of correction depend on the product, placement and cause of the problem. Do not assume that dissolving is a guaranteed “undo” button; discuss treatment scenarios beforehand.

Must Structura be given on the same day as botulinum toxin or a device procedure?

No. The Structura instructions expressly prohibit concurrent laser resurfacing and medium-to-deep peeling. For botulinum toxin and other methods, compatibility and intervals require review of both instructions and the clinical plan. Ask why combining treatments is preferable to assessing them separately.

Can it replace the treatment of sudden facial weight loss?

No. Unintentional loss of weight and facial volume deserves medical investigation; an aesthetic injection cannot replace diagnosis or treatment of the underlying cause.

Sources and documents

1. IBSA Derma, official Profhilo product line (including Structura)
2. TGA, Australian Register of Therapeutic Goods, ARTG 458194
3. TGA, official cancellation notice for ARTG 458194
4. TGA, Australian Register of Therapeutic Goods, ARTG 473805
5. Cassuto et al., Gels 2023, clinical case series
6. Sparavigna et al., Health Science Reports 2024, observational pilot
7. FDA, Dermal Fillers safety
8. IBSA Derma, official Profhilo Structura instructions for use (multilingual)